Lymphoma Subtype Classification

Identify risk of being diagnosed with Lymphoma

The Cancer Genome Characterization Initiatives (CGCI) program supports cutting-edge genomics research of adult and pediatric cancers. CGCI investigators develop and apply advanced sequencing methods that examine genomes, exomes, and transcriptomes within various types of tumors. The program includes Burkitt Lymphoma Genome Sequencing Project (BLGSP) project and HIV+ Tumor Molecular Characterization Project - Cervical Cancer (HTMCP-CC) project. The dataset contains open Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, and miRNA Expression Quantification data. This dataset also contains controlled WGS/Targeted Sequencing/RNA-Seq/miRNA-Seq Aligned Reads, and RNA-Seq Splice Junction Quantification

The goal of the project is to identify recurrent genetic alterations (mutations, deletions, amplifications, rearrangements) and/or gene expression signatures. National Cancer Institute (NCI) utilized whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing. The samples were processed and submitted for genomic characterization using pipelines and procedures established within The Cancer Genome Analysis (TCGA) project.

The study describes integrative analysis of genetic lesions in 574 diffuse large B cell lymphomas (DLBCL) involving exome and transcriptome sequencing, array-based DNA copy number analysis and targeted amplicon resequencing. The dataset contains open RNA-Seq Gene Expression Quantification data.